LGM
ALNY icon

Logos Global Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Logos Global Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-35,000
Closed -$5.93M – 49
2021
Q4 		$5.93M Buy
+35,000
New +$6.51M 0.61% 36
2020
Q2 		– Sell
-39,644
Closed -$4.32M – 48
2020
Q1 		$4.32M Buy
+39,644
New +$4.58M 1.64% 24

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Logos Global Management's ALNY Position: Q1 2022 in Review

Logos Global Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2022, closing a stake of 35,000 shares — an estimated $5.93M sold.

Logos Global Management first reported a position in ALNY in Q1 2020 and held it in 2 quarters. The position peaked at $5.93M in Q4 2021. 443 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

  • Logos Global Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Logos Global Management sold 35,000 Alnylam Pharmaceuticals shares in Q1 2022, an estimated $5.93M.
  • Logos Global Management first reported a position in Alnylam Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • Logos Global Management's Alnylam Pharmaceuticals position peaked at $5.93M in Q4 2021.
  • 443 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on Logos Global Management's 13F filing for Q1 2022, filed 16 May 2022.